medicalhealthnews

First, the chatbot finds out what’s in your fridge, then why you argued with your partner and what you’re most afraid of. For some users, the habit of seeking advice from an AI gradually turns into attachment, and its “opinion” starts to carry weight.
This kind of trust can become dangerous if artificial intelligence starts reinforcing a person’s beliefs, including those that are not very rational. Such cases are called “AI psychosis.” We look at how conversations with chatbots affect mental health and what doctors think about this phenomenon.

Minerva Neurosciences reported GAAP net income of $100.7 million for the third quarter of 2026, driven by a non-cash gain of $109.6 million from the change in fair value of warrant liabilities. Excluding this gain and stock-based compensation expense, the company’s adjusted net loss was $5.6 million. Cash, cash equivalents, marketable securities, and restricted cash totaled $77.0 million as of September 30, 2026.

Immunocore reported revenue of $102.2 million for the third quarter of 2026, compared with $103.7 million a year earlier, and a net loss of $14.2 million. Revenue for the first nine months increased from $295.5 million to $324.8 million. The company also reported progress in its programs targeting melanoma, infectious diseases, and autoimmune diseases.

CG Oncology reported revenue of $1.6 million and a net loss of $56.9 million, or $0.64 per share, for the third quarter of 2026. As of September 30, cash, cash equivalents, and marketable securities totaled $984.5 million. The company expects these funds to finance operations through the end of 2029. By year-end, the company expects to achieve several important clinical trial and regulatory milestones.

Filana Therapeutics reported a net loss of $10.7 million, or $0.22 per share, for the third quarter of 2026. As of September 30, cash and cash equivalents totaled $47.0 million. The company said that in September, the FDA lifted the clinical hold on trials of simufilam for the treatment of tuberous sclerosis-associated epilepsy. Patient enrollment for the planned Phase 2a study is expected to begin by the first quarter of 2027.

Extending life has stopped being a conversation topic for futurists and billionaires discussing immortality on a yacht. By 2026, it’s already a full-fledged investment industry: venture funds, pharma corporations, banks, and family offices are putting money into it.
According to the Eurasian Development Bank, the global biotechnology market has already reached about $2 trillion and by 2034 could come close to $5.9 trillion. This explains the steady interest of capital in the longevity sector and related technologies.

Rafael Holdings Inc Class B shares (New York:RFL) fell 25% in Wednesday premarket trading after the company reported a failure in a Phase 3 clinical trial of its Trappsol Cyclo drug for the treatment of Niemann-Pick disease type C: the study did not reach its primary endpoint.
In the TransportNPC study, which involved 94 patients, it was found that Trappsol Cyclo did not demonstrate a statistically significant result for the primary endpoint — a change in the score on the 4-domain Clinical Severity Scale for NPC at Week 96. The drug showed a favorable therapeutic effect versus placebo, slowing disease progression by 64%, but the result did not reach statistical significance: the p-value was 0.19.

In early August 2026, the U.S. regulator the FDA approved o?veporex?ton (Orzeyful) from Takeda — the first-ever drug that treats pathological sleepiness, type 1 narcolepsy, not just its symptoms but its cause. Analysts at Morgan Stanley estimate that the potential market for such drugs will grow to $16 billion by 2035, The Economist reports. However, the potential applications for drugs of this kind are much broader: scientists hope they can also help treat other sleep disorders, as well as common conditions such as attention deficit hyperactivity disorder (ADHD) and depression. Potentially, this could be a breakthrough comparable to the discovery of weight-loss drugs based on GLP-1, such as Ozempic. Who should we watch in this race?

Nautilus Biotechnology reported revenue of $234,000 for the third quarter of 2026 and a net loss of $15.6 million. Operating expenses were $16.9 million, and cash, cash equivalents, and investments totaled $114.3 million as of September 30, 2026. The company noted progress in developing methods for analyzing proteoforms and its Voyager platform.

Adding Bayer's NUBEQA to ADT and radiotherapy reduced the risk of metastasis or death by 58% (HR 0.42; p=0.0001) in patients with high-risk recurrent prostate cancer; 4-year metastasis-free survival was 95% versus 88%; the safety profile was consistent with expectations.

Novo Nordisk is open to the possibility of upgrading the status of its American listing by moving to a direct listing of shares on the New York Stock Exchange, the company's CEO, Mike Dostdar, said in an interview with the Financial Times published on Wednesday.
Dostdar said that he sees advantages in such a move, but уточнил that the company is not currently actively considering this idea.

Deutsche Bank downgraded Novo Nordisk (New York: NVO) (CSE: NOVOb) from “hold” to “sell” and cut the target stock price by 9%—to 265 Danish kroner from 290 kroner—citing ongoing concerns about the company’s growth pace. On Thursday, the shares fell by more than 3% during trading in Copenhagen.

Agenus reported revenue of $31.5 million, operating income of $11.4 million, and net income of $2.8 million for the third quarter of 2026. At the end of September, the company had $86.9 million in cash, cash equivalents, and short-term investments. Agenus is also preparing for the Phase 3 ROBBIN trial and announced that it had received the world’s first marketing approvals for BOT+BAL in Armenia.

Aardvark Therapeutics shares plunged 65% on October 23. Its drug for suppressing hunger in people with Prader-Willi syndrome showed only a slight advantage over placebo, according to published data from the prematurely terminated third-phase clinical trial. These results cannot be considered final — in February, Aardvark suspended the trial because of heart problems in one of the participants, but on October 22 the U.S. regulator allowed testing to continue.

Shares of Lexicon Pharmaceuticals Inc (NASDAQ:LXRX) rose by more than 13% during trading on Monday morning after the Wall Street research firm Cantor Fitzgerald began coverage of the stock with a positive outlook. The broker assigned the biopharmaceutical company a “Buy Above the Market” rating and set a target price of $8.00, reflecting significant upside potential driven by the company’s ongoing late-stage cardiology research program.